We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Former FDA Chief: Use Registries to Test Efficacy Postmarketing
Former FDA Chief: Use Registries to Test Efficacy Postmarketing
April 18, 2012
For the U.S. to speed new drugs to market and retain its innovative lead, the “FDA should approve drugs based on safety and leave efficacy testing for postmarket studies,” former commissioner Andrew von Eschenbach proposed in a recent opinion piece in The Wall Street Journal.